Revvity Inc.
RVTY Healthcare Diagnostics & Research
Revvity Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 3.67% from fiscal 2024.
- Revenue
- +4.29%
- EPS
- +2.17%
- Free cash flow
- +27.0%
- Total debt
- −18.1%
Quarter to September 2026, against a year earlier
Follow RVTY
Alert me
Revvity Inc. (RVTY) valuation and DCF model
At $150.97 the price implies free cash flow after share-based pay growing 12.3% a year for ten years.
Free cash flow after share-based pay grew 6.4% a year over the last ten years, −17.1% over the last five. The price asks for about twice its ten-year rate. The industry’s median company is priced for 15.8%.
In December 2017 the price assumed 11.1% a year; Revvity Inc. went on to grow free cash flow after share-based pay 10.1% a year to FY2025.
- The price needs
- 12.3% a year for ten years
- $150.97
- today’s price
- Its base case
- 6.4% a year for five years, then 3.9%
- $81.68
- 45.9% below today’s price
Base case on its own ten-year record Revvity Inc.’s own growth, carried forward
Its assumptions
Powerpack lets you start from a scenario and type over any of them.
How we got there$4.91b 10 years of cash to equity+$6.36b terminal value−$2.04b net debt=$9.23b equity value÷112.98m shares=$81.68 per share
Valuation against its own history
| Multiple | Current | 5Y avg | 10Y avg | vs 10Y avg | Industry median | vs industry | 10Y range |
|---|---|---|---|---|---|---|---|
| P/E | 71.89× | 43.96× | 37.93× | 90% above | 34.52× | 108% above | |
| P/FCF | 28.19× | 582.89× | 305.59× | 91% below | 33.51× | 16% below | |
| P/B | 2.33× | 1.97× | 2.78× | 16% below | 3.42× | 32% below | |
| EV/EBITDA | 25.08× | 20.48× | 20.10× | 25% above | 23.44× | 7% above | |
| EV/Sales | 6.61× | 5.89× | 5.59× | 18% above | 5.18× | 28% above |
RVTY trades at 71.89× P/E, against a 10-year average of 37.93× (range 20.08×–71.89×). That is dearer than 100% of the last 9 year-end readings; re-rating to the average implies $79.65 per share.